DE69925366D1 - N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin-mesylat-anhydrat und -monohydrat - Google Patents

N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin-mesylat-anhydrat und -monohydrat

Info

Publication number
DE69925366D1
DE69925366D1 DE69925366T DE69925366T DE69925366D1 DE 69925366 D1 DE69925366 D1 DE 69925366D1 DE 69925366 T DE69925366 T DE 69925366T DE 69925366 T DE69925366 T DE 69925366T DE 69925366 D1 DE69925366 D1 DE 69925366D1
Authority
DE
Germany
Prior art keywords
ethinylphenylamino
chinazolinamine
methoxyethoxy
monohydrate
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925366T
Other languages
English (en)
Other versions
DE69925366T2 (de
Inventor
John Allen
Timothy Norris
William Raggon
Paul Santafianos
Mysore Shanker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSI Pharmaceuticals LLC filed Critical OSI Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69925366D1 publication Critical patent/DE69925366D1/de
Publication of DE69925366T2 publication Critical patent/DE69925366T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69925366T 1998-04-29 1999-04-08 N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin-mesylat-anhydrat und -monohydrat Expired - Lifetime DE69925366T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29
US83441P 1998-04-29
PCT/IB1999/000612 WO1999055683A1 (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Publications (2)

Publication Number Publication Date
DE69925366D1 true DE69925366D1 (de) 2005-06-23
DE69925366T2 DE69925366T2 (de) 2006-03-09

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925366T Expired - Lifetime DE69925366T2 (de) 1998-04-29 1999-04-08 N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-chinazolinamin-mesylat-anhydrat und -monohydrat

Country Status (41)

Country Link
EP (1) EP1076652B1 (de)
JP (1) JP4652569B2 (de)
KR (1) KR100668412B1 (de)
CN (2) CN1298396A (de)
AP (1) AP1252A (de)
AR (1) AR018201A1 (de)
AT (1) ATE295839T1 (de)
AU (1) AU759691C (de)
BR (1) BR9910025A (de)
CA (1) CA2330447C (de)
CO (1) CO5060467A1 (de)
CZ (1) CZ298230B6 (de)
DE (1) DE69925366T2 (de)
DZ (1) DZ2777A1 (de)
EA (1) EA002836B1 (de)
EG (1) EG24000A (de)
ES (1) ES2238825T3 (de)
GT (1) GT199900063A (de)
HN (1) HN1999000057A (de)
HU (1) HU227569B1 (de)
ID (1) ID27198A (de)
IL (1) IL139172A0 (de)
MA (1) MA26624A1 (de)
ME (1) MEP42008A (de)
MX (1) MXPA00010610A (de)
MY (1) MY136033A (de)
NO (1) NO317301B1 (de)
NZ (1) NZ508154A (de)
OA (1) OA11769A (de)
PA (1) PA8471001A1 (de)
PE (1) PE20000441A1 (de)
PL (1) PL196940B1 (de)
RS (1) RS50081B (de)
SA (1) SA99200216B1 (de)
TN (1) TNSN99079A1 (de)
TR (1) TR200003166T2 (de)
TW (1) TWI248437B (de)
UA (1) UA60363C2 (de)
UY (1) UY26099A1 (de)
WO (1) WO1999055683A1 (de)
ZA (1) ZA992972B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
EP1680426B1 (de) 2003-06-10 2007-09-19 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivative
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
WO2006083458A2 (en) 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
WO2008122776A2 (en) * 2007-04-04 2008-10-16 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
WO2009024989A2 (en) 2007-08-17 2009-02-26 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
EP2411373B1 (de) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Verfahren zur herstellung von erlotinib oder dessen pharmazeutisch unbedenklichen salzen
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
HN1999000057A (es) 1999-09-29
CA2330447A1 (en) 1999-11-04
TR200003166T2 (tr) 2001-02-21
AP1252A (en) 2004-02-25
ES2238825T3 (es) 2005-09-01
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
TNSN99079A1 (fr) 2005-11-10
WO1999055683A1 (en) 1999-11-04
NZ508154A (en) 2003-07-25
RS50081B (sr) 2009-01-22
CN101219999A (zh) 2008-07-16
HUP0101818A1 (hu) 2002-03-28
UA60363C2 (uk) 2003-10-15
ZA992972B (en) 2000-10-30
TWI248437B (en) 2006-02-01
OA11769A (en) 2005-07-25
JP2002513009A (ja) 2002-05-08
PL196940B1 (pl) 2008-02-29
KR100668412B1 (ko) 2007-01-12
ATE295839T1 (de) 2005-06-15
CA2330447C (en) 2009-06-30
NO20005453L (no) 2000-12-20
MEP42008A (en) 2011-02-10
BR9910025A (pt) 2000-12-26
PL343766A1 (en) 2001-09-10
MY136033A (en) 2008-07-31
MXPA00010610A (es) 2002-07-02
PE20000441A1 (es) 2000-05-23
IL139172A0 (en) 2001-11-25
NO20005453D0 (no) 2000-10-27
CZ298230B6 (cs) 2007-08-01
AU759691C (en) 2004-04-29
JP4652569B2 (ja) 2011-03-16
EA200001112A1 (ru) 2001-04-23
AU759691B2 (en) 2003-04-17
NO317301B1 (no) 2004-10-04
EG24000A (en) 2008-03-19
CO5060467A1 (es) 2001-07-30
CZ20003974A3 (en) 2001-05-16
HU227569B1 (en) 2011-08-29
GT199900063A (es) 2000-10-20
PA8471001A1 (es) 2000-09-29
AU2850999A (en) 1999-11-16
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
KR20010078710A (ko) 2001-08-21
AP9901523A0 (en) 1999-06-30
MA26624A1 (fr) 2004-12-20
EA002836B1 (ru) 2002-10-31
ID27198A (id) 2001-03-08
HK1037180A1 (en) 2002-02-01
EP1076652A1 (de) 2001-02-21
CN1298396A (zh) 2001-06-06
SA99200216B1 (ar) 2006-06-04
AR018201A1 (es) 2001-10-31
EP1076652B1 (de) 2005-05-18
HUP0101818A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE295839T1 (de) N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethox )-4-chinazolinamin-mesylat-anhydrat und -monohydrat
ATE240327T1 (de) 1,2-annelierte chinolinderivate
NO20013003D0 (no) Kinolin-derivater
ATE417847T1 (de) Chinazolin- und pyridopyrimidinderivate
DK1073639T3 (da) Chinolinderivater
ATE250036T1 (de) Chinolinderivate
EE200300071A (et) Kinasoliini derivaadid
BR9914167B1 (pt) compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
EE200300325A (et) Asendatud amiini derivaadid ning nende kasutamismeetodid
NO326461B1 (no) Rommersko
ATE229005T1 (de) Chinolinderivate
NO20012473L (no) Kinolin-4-karboksamidderivater som NK-3 og NK-2 reseptorantagonister
NO20021115L (no) Ny sammensetning
DE59905647D1 (de) Funkgerät
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
DE69903961D1 (de) Muscarinagonisten und antagonisten
DE69930340D1 (de) Reibahle
FI980517A0 (fi) Foerfarande foer handover
DK199901730A (da) Ny Sammensætning
NO20014127D0 (no) 5-HT1F agonister
DE69930946D1 (de) Thermokopf, thermokopfeinheit und herstellungsverfahren dafür
DE60005282D1 (de) Golfschlägerkopf, golfschläger und golfschlägerset
DK1122253T3 (da) Quinazolinonderivater
SE9800815D0 (sv) Bio-chelating agents, high affinity bio-target antagonists
NO20015444D0 (no) Ny fremgangsmåte

Legal Events

Date Code Title Description
8364 No opposition during term of opposition